Technical Analysis for AKCA - Akcea Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 21.055 -5.03% -1.12
AKCA closed up 11.3 percent on Tuesday, May 21, 2019, on 1.22 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical AKCA trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup -5.03%
Wide Bands Range Expansion -5.03%
Oversold Stochastic Weakness -5.03%
New 52 Week Closing Low Bearish 5.70%
New 52 Week Low Weakness 5.70%
Multiple of Ten Bearish Other 5.70%
Wide Bands Range Expansion 5.70%
Gapped Down Weakness 5.70%
Oversold Stochastic Weakness 5.70%
New 52 Week Closing Low Bearish 1.81%

Older signals for AKCA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).
Biopharmaceutical Medical Specialties Cardiology Dyslipidemia Low Density Lipoprotein Lipids Lipoproteins Antisense RNA Lipid Disorders Lipoprotein Lipase Deficiency Familial Chylomicronemia Syndrome Familial Partial Lipodystrophy
Is AKCA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 40.75
52 Week Low 19.67
Average Volume 236,063
200-Day Moving Average 28.6699
50-Day Moving Average 27.1328
20-Day Moving Average 24.065
10-Day Moving Average 22.009
Average True Range 1.3526
ADX 38.84
+DI 19.4277
-DI 32.5538
Chandelier Exit (Long, 3 ATRs ) 24.3222
Chandelier Exit (Short, 3 ATRs ) 23.7278
Upper Bollinger Band 28.8121
Lower Bollinger Band 19.3179
Percent B (%b) 0.3
BandWidth 39.452317
MACD Line -1.8854
MACD Signal Line -1.6834
MACD Histogram -0.202
Fundamentals Value
Market Cap 1.42 Billion
Num Shares 63.9 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -11.73
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.77
Resistance 3 (R3) 25.46 23.95 25.17
Resistance 2 (R2) 23.95 23.03 24.11 24.97
Resistance 1 (R1) 23.06 22.47 23.51 23.37 24.77
Pivot Point 21.55 21.55 21.77 21.71 21.55
Support 1 (S1) 20.66 20.63 21.11 20.97 19.57
Support 2 (S2) 19.15 20.07 19.31 19.37
Support 3 (S3) 18.26 19.15 19.17
Support 4 (S4) 18.57